Latest Insider Transactions at Ionis Pharmaceuticals Inc (IONS)
This section provides a real-time view of insider transactions for Ionis Pharmaceuticals Inc (IONS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IONIS PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IONIS PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 26
2021
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Other acquisition or disposition
|
Direct |
197
+0.73%
|
$8,668
$44.54 P/Share
|
|
Feb 26
2021
|
Eric Swayze EVP Research |
BUY
Other acquisition or disposition
|
Direct |
460
+3.91%
|
$20,240
$44.54 P/Share
|
|
Jan 28
2021
|
Brett P Monia Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,306
-2.54%
|
$78,360
$60.69 P/Share
|
|
Jan 28
2021
|
Brett P Monia Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,634
+4.87%
|
-
|
|
Jan 26
2021
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Open market or private sale
|
Direct |
28,333
-93.34%
|
$1,784,979
$63.74 P/Share
|
|
Jan 25
2021
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
5,324
-16.73%
|
$335,412
$63.5 P/Share
|
|
Jan 22
2021
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
40,000
-7.49%
|
$2,440,000
$61.67 P/Share
|
|
Jan 21
2021
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
35,000
-3.12%
|
$2,135,000
$61.09 P/Share
|
|
Jan 15
2021
|
Eric Swayze EVP Research |
SELL
Payment of exercise price or tax liability
|
Direct |
3,216
-22.89%
|
$196,176
$61.28 P/Share
|
|
Jan 15
2021
|
Eric Swayze EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
8,944
+38.9%
|
-
|
|
Jan 15
2021
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Payment of exercise price or tax liability
|
Direct |
2,718
-28.25%
|
$165,798
$61.28 P/Share
|
|
Jan 15
2021
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
7,503
+43.82%
|
-
|
|
Jan 15
2021
|
B Lynne Parshall Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,741
-4.02%
|
$167,201
$61.28 P/Share
|
|
Jan 15
2021
|
B Lynne Parshall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,655
+13.53%
|
-
|
|
Jan 15
2021
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
5,856
-15.54%
|
$357,216
$61.28 P/Share
|
|
Jan 15
2021
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
16,504
+30.46%
|
-
|
|
Jan 15
2021
|
Brett P Monia Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,927
-23.43%
|
$910,547
$61.28 P/Share
|
|
Jan 15
2021
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,823
+35.34%
|
-
|
|
Jan 15
2021
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,175
-12.44%
|
$376,675
$61.28 P/Share
|
|
Jan 15
2021
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,151
+25.68%
|
-
|
|
Jan 15
2021
|
Richard S Geary EVP, Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,398
-13.36%
|
$390,278
$61.28 P/Share
|
|
Jan 15
2021
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,598
+26.87%
|
-
|
|
Jan 15
2021
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,488
-11.43%
|
$334,768
$61.28 P/Share
|
|
Jan 15
2021
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,520
+24.43%
|
-
|
|
Jan 15
2021
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Indirect |
1,434
-31.55%
|
$87,474
$61.28 P/Share
|
|
Jan 15
2021
|
Stanley T Crooke Exec Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Indirect |
4,371
+49.02%
|
-
|
|
Jan 15
2021
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
18,924
-38.4%
|
$1,154,364
$61.28 P/Share
|
|
Jan 15
2021
|
Stanley T Crooke Exec Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
47,257
+48.95%
|
-
|
|
Jan 13
2021
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
141
-0.46%
|
$8,319
$59.5 P/Share
|
|
Jan 05
2021
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
195
-3.68%
|
$10,725
$55.99 P/Share
|
|
Dec 23
2020
|
B Lynne Parshall Director |
SELL
Open market or private sale
|
Direct |
10,000
-14.82%
|
$600,000
$60.0 P/Share
|
|
Dec 17
2020
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
1,407
-88.99%
|
$70,350
$50.5 P/Share
|
|
Dec 15
2020
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
39,000
-6.1%
|
$1,911,000
$49.77 P/Share
|
|
Dec 07
2020
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
11,000
-0.85%
|
$561,000
$51.68 P/Share
|
|
Dec 04
2020
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,947
-19.66%
|
$405,297
$51.04 P/Share
|
|
Dec 04
2020
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,947
+16.43%
|
$309,933
$39.87 P/Share
|
|
Dec 04
2020
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
23,840
-45.22%
|
$1,215,840
$51.04 P/Share
|
|
Dec 04
2020
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,840
+31.14%
|
$929,760
$39.87 P/Share
|
|
Dec 02
2020
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,160
-42.29%
|
$1,079,160
$51.32 P/Share
|
|
Dec 02
2020
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,160
+29.72%
|
$825,240
$39.87 P/Share
|
|
Dec 02
2020
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,053
-17.84%
|
$359,703
$51.32 P/Share
|
|
Dec 02
2020
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,053
+15.14%
|
$275,067
$39.87 P/Share
|
|
Nov 25
2020
|
B Lynne Parshall Director |
SELL
Open market or private sale
|
Direct |
3,590
-5.05%
|
$179,500
$50.05 P/Share
|
|
Nov 25
2020
|
B Lynne Parshall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,590
+4.81%
|
$140,010
$39.87 P/Share
|
|
Nov 25
2020
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
11,920
-28.14%
|
$596,000
$50.05 P/Share
|
|
Nov 25
2020
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,920
+21.96%
|
$464,880
$39.87 P/Share
|
|
Nov 25
2020
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Open market or private sale
|
Direct |
12,990
-86.54%
|
$649,500
$50.05 P/Share
|
|
Nov 25
2020
|
Stanley T Crooke Exec Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
12,990
+46.39%
|
$506,610
$39.87 P/Share
|
|
Nov 25
2020
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
21,680
-40.02%
|
$1,084,000
$50.05 P/Share
|
|
Nov 25
2020
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,680
+28.58%
|
$845,520
$39.87 P/Share
|